Comparison Of Selling vs. Manufacturing Biosimilars

By ISR Reports

In Q42017, ISR surveyed 177 professionals from biopharmaceutical sponsors to ask about their companies’ current stances on selling and on manufacturing biosimilars. By looking at the differences in stances on selling versus manufacturing biosimilars, the data show there is some opportunity for CMOs to secure biosimilar manufacturing projects.